These findings support the hypothesis that BRCA1 mRNA expression levels could be a valid indicator of differential sensitivity to cisplatin or docetaxel in esophageal cancer, which is consistent with findings in previous clinical studies on other malignancies [23]–[31]. Here, BRCA1 is linked to esophageal cancer.